MedTrace Logo

Comparative Effectiveness Clinical Trial of MST Compared to ECT in Major Depressive Disorder

NCT04216095 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2020-01-03

No results posted yet for this study

Summary

This study was a prospective, open-label comparative effectiveness clinical trial, comparing magnetic seizure therapy (MST) to ECT in patients with Major Depressive Disorder (MDD).

Conditions

Interventions

DEVICE

Electroconvulsive Therapy (n=30)

Right unilateral (RUL) ECT (n=15) or bitemporal (BT) ECT (n=15) using a Thymatron IV device (Somatics LLC, USA) twice weekly.

DEVICE

Magnetic Seizure Therapy (n=30)

High-dose magnetic seizure therapy (HD-MST) over the vertex using Magstim Theta device (Magstim Company Limited, Whitfield, Wales, UK) at 100% maximal output of the device (constant), with pulse frequency 100Hz and train duration 10 seconds twice weekly.

Sponsors & Collaborators

  • Nagy A. Youssef (Consultant on the MST technique)

    collaborator UNKNOWN

  • Tanta University

    lead OTHER

Principal Investigators

  • Fatma El-Deeb, MD, PhD · Tanta University, Faculty of Medicine

  • El-Sayed Gad, MD, PhD · Tanta University, Faculty of Medicine

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-06-07
Primary Completion
2015-10-07
Completion
2015-10-07

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04216095 on ClinicalTrials.gov